What healthcare professionals need to know about prescribing and training for Mounjaro

What does formal Mounjaro prescriber training actually cover in the UK?

There is no single mandated national curriculum for Mounjaro prescriber training in the UK, but professional expectation (shaped by the MHRA's Black Triangle requirements, NICE TA1026, and the NHS England tirzepatide-in-primary-care guidance) is clear about what clinical competency looks like. Professionals need a working grasp of the dual-agonist mechanism: tirzepatide activates both GIP and GLP-1 receptors, which reduces appetite and slows gastric emptying through two complementary pathways. That mechanism is also why the contraceptive-pill absorption interaction is specific to tirzepatide, not shared equally with semaglutide-based treatments.

Training content that features in accredited courses typically includes: patient selection against licensed BMI criteria (BMI ≥30, or ≥27 with at least one weight-related condition); comorbidity screening; the graduated dose schedule from 2.5 mg through to 15 mg; gastrointestinal tolerability and how to counsel patients through the early weeks; acute pancreatitis recognition (the MHRA issued a Drug Safety Update in January 2026 highlighting this risk across GLP-1 medicines); and stopping-rule criteria per NICE. For nurses and pharmacists working as Independent Prescribers, the scope is broader still. Our clinical team overview at the nume clinical team page — sorry, at the nume clinical team page gives a sense of what prescriber-led oversight looks like in practice.

Structured Mounjaro training courses in the UK are available through several providers, ranging from half-day in-person workshops to online self-study modules, and cover both the clinical and legislative dimensions of prescribing a Black Triangle POM. Worth verifying that any course explicitly references NICE TA1026 and the current SmPC.

What are the prescribing criteria a clinician must apply at the point of patient assessment?

The licensed criteria for Mounjaro in weight management are set out in the product's Summary of Product Characteristics and referenced in NICE's appraisal of tirzepatide (TA1026). For private prescribing, the SmPC criteria apply directly: adults aged 18 and over with a BMI of 30 or above, or 27–29.9 with at least one weight-related comorbidity such as hypertension, dyslipidaemia, type 2 diabetes, or obstructive sleep apnoea. For NHS prescribing under NICE TA1026, the criteria are stricter and phased. As of June 2025, the qualifying threshold for NHS patients is BMI ≥40 with four or more of five specified conditions; a second cohort at BMI 35–39.9 with four or more conditions was activated in June 2026.

BMI thresholds throughout are adjusted downward by 2.5 kg/m² for adults from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. Prescribers should document this adjustment where applicable. Contraindications include personal or family history of medullary thyroid carcinoma, MEN type 2 syndrome, and a previous episode of pancreatitis. Pregnancy, breastfeeding, and actively trying to conceive are also contraindications, with the MHRA advising effective contraception and a clinical wash-out discussion before conception is planned.

The contraception counselling point carries an additional tirzepatide-specific requirement: women using oral contraceptives should be counselled to add a non-oral barrier method for the first four weeks of treatment and for four weeks after any dose increase, because gastric-emptying effects may reduce pill absorption. This is documented in NHS England's weight-management injections guidance. No equivalent evidence exists for the same interaction with semaglutide.

How should prescribers approach ongoing monitoring and dose titration?

Treatment initiation is only the start of the prescriber's clinical involvement. The 2.5 mg starting dose is a tolerability step, the first pen's purpose is giving the patient's digestive system time to adjust, not driving measurable weight loss. Dose increases happen roughly every four weeks, but the prescriber, not a default calendar, decides when each step is appropriate based on tolerability. Some patients remain at a given dose for longer if gastrointestinal effects are still settling; pushing the schedule when a patient is actively struggling with nausea or diarrhoea usually backfires.

Monitoring priorities include weight at each clinical review, gastrointestinal symptoms, any symptoms consistent with pancreatitis (severe upper abdominal pain reaching the back), gallbladder symptoms, and (where relevant) blood glucose in patients with type 2 diabetes. The NICE stopping rule is explicit: if a patient has not achieved at least 5% weight loss after six months on the highest dose they can tolerate, continuing treatment should be reviewed. Professionals should document this assessment.

For clinicians wanting to understand the broader health context these patients bring to a consultation, the Mounjaro and existing health conditions page covers relevant comorbidities in detail. Likewise, understanding how patients can support their health during treatment (protein adequacy, hydration, activity) informs the lifestyle counselling component that NICE expects alongside pharmacological treatment.

Where does an online pharmacy like nume fit into the wider prescribing landscape?

A GPhC-registered online pharmacy offering Mounjaro through a private prescription sits within the same regulatory framework as any high-street dispensing pharmacy. The prescription must come from a registered prescriber, the medicines must be sourced through the licensed UK supply chain, and the dispensing pharmacy must hold a valid GPhC premises registration, verifiable in seconds at the GPhC pharmacy register. Checking that register before recommending or referring a patient to any online service is a one-minute habit that protects patients.

For healthcare professionals who are themselves exploring tirzepatide (either as Independent Prescribers wanting to understand how private services operate, or as patients in their own right) the tirzepatide clinical overview provides a UK-focused summary of the evidence base, including SURMOUNT-1 and the SURMOUNT-5 head-to-head data. The cost picture for patients is covered on our Mounjaro cost page, including the context behind Eli Lilly's September 2025 UK list-price revision.

Professionals interested in structured online learning may find a free online Mounjaro training course a useful starting point, though the depth and accreditation of individual offerings vary. Any course that does not reference the current NICE TA1026 eligibility criteria or the Black Triangle pharmacovigilance requirements should be treated as incomplete. And for patients referred by a professional, or arriving independently, our weight-loss treatment overview explains what a private clinical pathway looks like from first enquiry through to aftercare.